wire - news in brief
Health - Oct 16
Health - Oct 16
By identifying a protein that helps regulate blood glucose and lipids, researchers at UNIGE hope for the rapid development of treatments more effective than current insulin therapy.
Environment - Oct 16
Ecosystems provide numerous benefits, supplying food, clean water and other resources. So, it is vital that ecosystem stability is maintained in the face of disturbances such as drought, heatwaves or nutrient inputs.
Category
Results 1 - 50 of 371.
As part of its 50th anniversary celebration, EPFL is highlighting his commitment for open and reproducible research through an exceptional Open Science Day, today.
Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control
A number of researchers have published critical comments about an ETH Zurich study that generated a lot of interest with its quantitative assessment of the technical potential that reforestation holds for reducing CO2. In the following interview, Professor Detlef Günther, Vice President for Research and Corporate Relations, explains why he welcomes this discourse.
Gerd Folkers was the first head of Critical Thinking ETH (CTETH) and left an indelible mark on the initiative.
Only one out of a hundred houses per year are renovated to make them more energy efficient - less than half the number needed to achieve the goals of the Energy Strategy 2050 for buildings. The National Research Programme "Energy" shows that the necessary technologies are available, but there is a lack of appropriate planning, building and energy laws, as well as of expertise.
ETH scores highly on interdisciplinarity
Two ETH Zurich projects and one with ETH involvement have been awarded one of the coveted ERC Synergy Grants. These EU grants offer up to EUR 14 million to promote interdisciplinary collaboration on research projects. Correlations and questions in research are becoming more and more complex, which makes collabo-ration between researchers from different fields necessary.
Two ETH Zurich projects and one with ETH involvement have been awarded one of the coveted ERC Synergy Grants. These EU grants offer up to EUR 14 million to promote interdisciplinary collaboration on research projects. Correlations and questions in research are becoming more and more complex, which makes collabo-ration between researchers from different fields necessary.
Two students from EPFL have developed a smart speaker with voice-activation technology that connects patients directly to their loved ones as well as caregivers and emergency services.
Romain Fleury, a tenure-track assistant professor who heads the Laboratory of Wave Engineering, has been named best teacher in electrical and electronic engineering.
Three researchers share this year's Nobel Prize in Chemistry. They are being honoured for their respective contributions in research that led to today's rechargeable lithium-ion batteries - and has made our smartphones and electric cars possible in their current form.
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustaine
Phase III PEMPHIX study shows Roche's MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustaine
ETH spinoff FenX transforms industrial waste into a porous foam suitable for building insulation. Unlike other sustainable materials used for the purpose, this type of insulation is non-flammable and inexpensive to produce.
The European Research Council has awarded one of the prestigious ERC Synergy Grants - the most competitive funding scheme from ERC - to a joint research project of the Friedrich Miescher Institute for Biomedical Research, the ETH Zurich and the University of Bristol. The interdisciplinary team wants to investigate the molecular mechanisms of viral infection, which will contribute to fundamental knowledge about cellular regulation and new concepts for broad-spectrum anti-viral therapy.
An aerodynamic bike that was designed using software from Neural Concept, a spin-off from the Computer Vision Laboratory (CVLab) in the EPFL School of Computer and Communication Sciences, has broken two world records for cycling speed.
Details of Dental Wear Revealed
The teeth of mammals experience constant wear. However, the details of these wear processes are largely unknown. Researchers at the University of Zurich have now demonstrated that the various areas of herbivores' teeth differ in how susceptible they are to dental wear, detailing an exact chronology.
The teeth of mammals experience constant wear. However, the details of these wear processes are largely unknown. Researchers at the University of Zurich have now demonstrated that the various areas of herbivores' teeth differ in how susceptible they are to dental wear, detailing an exact chronology.
"I regard myself as a descendent of the true Modernists," a young Rem Koolhaas told Dutch journal wonen-TA/BK in 1978.
Prostate cancer research, important SNF grant goes to the IOR
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana), has received a 4-year grant
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana), has received a 4-year grant
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
Whether mobile phone or automatic toilets - electronic devices are becoming increasingly complex. And who hasn't heard stories of devices that fail precisely after the warranty has expired?
Self-driving cars, the automatic detection of cancer cells, online translation: deep learning makes it all possible. The ETH spin-off Mirage Technologies has developed a deep learning platform that aims to help start-ups and companies more quickly develop and optimise their products. The name has a fairytale feel to it, with its reference to mirages and the suggestion of illusion.
AveXis presents updated STRONG data at WMS demonstrating a higher mean increase in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores among older SMA Type 2 patients following one-time intrathecal administration of AVXS-101
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Taking sustainability into space
Things are changing in outer space: it is filling with debris, attracting private companies, and raising new technological challenges.
Things are changing in outer space: it is filling with debris, attracting private companies, and raising new technological challenges.
These days, Microsoft officially opens a lab in Zurich dedicated to researching mixed reality technologies and artificial intelligence.
Marc Angélil played a decisive role in shaping the teaching of architecture at ETH Zurich, both as professor and as temporary head of the department.
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
They are 16, determined and ready to dive into the exciting world of research: the first Ph.D students from the new USI Faculty of Biomedical Sciences presented themselves on Friday 20 September at t
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
